An FDA approval is not a news event for an agency. It is a starting gun on a commercial build with a hard deadline, and the agency work is decided in the months before anyone is celebrating.
The commercial clock starts early
By the time a drug is approved, the launch plan is largely set. Agencies were selected months earlier. The disease awareness work, HCP education, patient identification, market access messaging, and launch campaign were all scoped while the approval was still pending.
Which means an agency reacting to the approval announcement is not early. It is roughly a year late.
The signals that actually precede the work
- PDUFA dates. These are public. A PDUFA date is a launch date with a question mark, and the commercial build precedes it.
- Positive pivotal data. The moment a Phase 3 reads out well, the company begins building commercially, because they now believe they will have a product.
- Breakthrough and priority review designations. These compress timelines and signal that a company will need to move commercially faster than they planned.
- Commercial leadership hiring. When a company starts recruiting a Chief Commercial Officer, market access leads, or a launch team, they are about to need agencies. This is one of the clearest and least watched signals in the industry.
- Acquisitions of late-stage assets. The acquirer needs to launch something they did not develop, often in a therapeutic area where they have no existing presence.
The greenfield opportunity nobody claims
The most valuable agency work often sits where there is no existing category. When a first-in-class drug approaches approval in a condition with no approved treatments, everything is open: disease awareness barely exists, physicians may not diagnose the condition reliably, patients may be unidentified.
That is enormous, high-value work, and it is visible in the pipeline years before anyone issues an RFP.
The pitch that lands
Demonstrate that you understand the specific commercial challenge of their asset: the diagnosis problem, the physician education gap, the access hurdle. You are not selling agency services. You are showing them you have already thought about the launch they are about to attempt.
Know who to call
There are drugs approaching approval right now in categories that do not yet exist. The agency work is being decided this quarter.
Get Signals for your BD team, $8,000/year for up to 5 seats
Or a single seat, $2,500/year
Every Friday: 15 to 20 tagged signals, a “Who To Call This Week” list of 10 prioritized targets with the trigger and a suggested opening line, and a monthly outreach playbook. Two-week free trial, no commitment. See also the buying signals biotech vendors keep missing.
Frequently asked questions
What signals should a pharma agency watch?
PDUFA dates, which are public and effectively launch dates with a question mark; positive pivotal trial data, which triggers commercial building; breakthrough and priority review designations, which compress timelines; commercial leadership hiring, one of the clearest and least watched signals; and acquisitions of late-stage assets the acquirer must now launch.
When are launch agencies actually selected?
Months before approval. By the time a drug is approved, the launch plan is largely set and agencies were chosen while the approval was still pending. An agency reacting to the approval announcement is roughly a year late to the decision that mattered.
What is the most valuable agency opportunity in pharma?
Greenfield launches, where a first-in-class drug approaches approval in a condition with no approved treatments. Disease awareness barely exists, physicians may not diagnose the condition reliably, and patients are unidentified, which makes for enormous, high-value work that is visible in the pipeline years before an RFP is issued.
